Insider Selling: Liquidia Co. (NASDAQ:LQDA) CFO Sells 23,370 Shares of Stock

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 23,370 shares of the business’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $275,298.60. Following the transaction, the chief financial officer now owns 401,755 shares in the company, valued at approximately $4,732,673.90. This represents a 5.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Michael Kaseta also recently made the following trade(s):

• On Monday, December 2nd, Michael Kaseta sold 1,091 shares of Liquidia stock. The shares were sold at an average price of $11.51, for a total value of $12,557.41.

Liquidia Trading Down 3.4 %

LQDA stock traded down $0.40 during midday trading on Tuesday, hitting $11.36. The company’s stock had a trading volume of 552,977 shares, compared to its average volume of 728,753. The company has a market cap of $961.48 million, a PE ratio of -6.97 and a beta of 0.23. Liquidia Co. has a 12 month low of $8.26 and a 12 month high of $16.99. The firm’s 50-day moving average is $11.18 and its 200-day moving average is $11.02.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on LQDA shares. Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of Liquidia in a report on Thursday, January 9th. HC Wainwright reiterated a “buy” rating and set a $29.00 target price on shares of Liquidia in a report on Thursday, November 14th. Lifesci Capital initiated coverage on Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price on the stock. Scotiabank initiated coverage on Liquidia in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 target price on the stock. Finally, Wells Fargo & Company started coverage on Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 target price on the stock. One analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Liquidia has a consensus rating of “Buy” and an average price target of $25.38.

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC bought a new position in shares of Liquidia during the 2nd quarter valued at $27,000. Clear Harbor Asset Management LLC bought a new position in shares of Liquidia during the 3rd quarter valued at $100,000. Signaturefd LLC lifted its holdings in shares of Liquidia by 38,400.0% during the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after buying an additional 9,984 shares during the period. Ballentine Partners LLC bought a new position in shares of Liquidia during the 3rd quarter valued at $110,000. Finally, Whitcomb & Hess Inc. lifted its holdings in shares of Liquidia by 10.2% during the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock valued at $116,000 after buying an additional 1,074 shares during the period. 64.54% of the stock is owned by institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).